Skip to main content

Prospective Randomized Control Trial to Compare the Role of Injection Cerebrolysin for 10 Days Duration Against Placebo in Operated Cases of Degenerative Cervical Myelopathy.

Publication ,  Journal Article
Sharma, A; Agrawal, H; Naseem, A; Marathe, N; Gajbhiye, K; Subramanian, S; Rocos, B
Published in: Spine (Phila Pa 1976)
March 1, 2023

STUDY DESIGN: Prospective randomized control trial. OBJECTIVE: To analyze outcomes following the injection of cerebrolysin in surgically treated patients with degenerative cervical myelopathy (DCM). SUMMARY OF BACKGROUND DATA: Previous research has concluded that superior functional outcomes are achieved with the use of cerebrolysin in surgically treated patients of DCM for 21 days. Our study has been conducted to analyze the use of this drug for a shorter duration (10 days) and compare its clinical efficacy. METHODS: Ninety operated cases of mild to severe DCM were randomized into two groups. Sixty patients received the injection Cerebrolysin for 10 days postoperatively. The remaining 30 patients received a placebo. Functional outcomes were measured using modified Japanese Orthopaedic Association (mJOA) scores and visual analogue scale (VAS). The American Spinal Injury Association (ASIA) scale was used to document neurological recovery. Hand function was assessed by measuring the grip strength and the upper limb function score the upper extremity motor mJOA plus upper extremity sensory mJOA score. Assessments were performed and preoperatively and postoperatively and at one-month, three-month, six-month, and one-year following surgery. RESULTS: Preoperative mJOA and VAS scores were comparable in both groups ( P >0.05). Both groups experienced an improvement in mJOA and VAS scores at all time-points during follow-up as compared with preoperative scores. However, the cerebrolysin group demonstrated significantly greater mJOA scores (16.37±1) when compared with the placebo (15.2±1.8) at one-year follow-up ( P <0.0001). Neurological improvement with cerebrolysin therapy was also superior ( P =0.04). No significant adverse reactions were documented. CONCLUSION: Injection cerebrolysin, when administered for 10 days postoperatively, can result in significantly greater neurological improvement and hand function in patients with DCM who also receive surgery.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Spine (Phila Pa 1976)

DOI

EISSN

1528-1159

Publication Date

March 1, 2023

Volume

48

Issue

5

Start / End Page

295 / 300

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Spinal Cord Diseases
  • Prospective Studies
  • Orthopedics
  • Humans
  • Cervical Vertebrae
  • 4201 Allied health and rehabilitation science
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sharma, A., Agrawal, H., Naseem, A., Marathe, N., Gajbhiye, K., Subramanian, S., & Rocos, B. (2023). Prospective Randomized Control Trial to Compare the Role of Injection Cerebrolysin for 10 Days Duration Against Placebo in Operated Cases of Degenerative Cervical Myelopathy. Spine (Phila Pa 1976), 48(5), 295–300. https://doi.org/10.1097/BRS.0000000000004542
Sharma, Ayush, Harsh Agrawal, Atif Naseem, Nandan Marathe, Komalchand Gajbhiye, Santhoshkumar Subramanian, and Brett Rocos. “Prospective Randomized Control Trial to Compare the Role of Injection Cerebrolysin for 10 Days Duration Against Placebo in Operated Cases of Degenerative Cervical Myelopathy.Spine (Phila Pa 1976) 48, no. 5 (March 1, 2023): 295–300. https://doi.org/10.1097/BRS.0000000000004542.
Sharma A, Agrawal H, Naseem A, Marathe N, Gajbhiye K, Subramanian S, et al. Prospective Randomized Control Trial to Compare the Role of Injection Cerebrolysin for 10 Days Duration Against Placebo in Operated Cases of Degenerative Cervical Myelopathy. Spine (Phila Pa 1976). 2023 Mar 1;48(5):295–300.
Sharma, Ayush, et al. “Prospective Randomized Control Trial to Compare the Role of Injection Cerebrolysin for 10 Days Duration Against Placebo in Operated Cases of Degenerative Cervical Myelopathy.Spine (Phila Pa 1976), vol. 48, no. 5, Mar. 2023, pp. 295–300. Pubmed, doi:10.1097/BRS.0000000000004542.
Sharma A, Agrawal H, Naseem A, Marathe N, Gajbhiye K, Subramanian S, Rocos B. Prospective Randomized Control Trial to Compare the Role of Injection Cerebrolysin for 10 Days Duration Against Placebo in Operated Cases of Degenerative Cervical Myelopathy. Spine (Phila Pa 1976). 2023 Mar 1;48(5):295–300.

Published In

Spine (Phila Pa 1976)

DOI

EISSN

1528-1159

Publication Date

March 1, 2023

Volume

48

Issue

5

Start / End Page

295 / 300

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Spinal Cord Diseases
  • Prospective Studies
  • Orthopedics
  • Humans
  • Cervical Vertebrae
  • 4201 Allied health and rehabilitation science
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1103 Clinical Sciences